Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Peptide Knowledge Center
All peptides

Liraglutide

Also known as: Victoza / Saxenda
FDA-Approved

Liraglutide is a daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).

Buy Liraglutide on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Liraglutide is a daily GLP-1 receptor agonist approved for type 2 diabetes (Victoza) and chronic weight management (Saxenda).

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

GLP-1 receptor agonism improves glycemic control and reduces appetite.

Current Research

LEADER trial demonstrated CV benefit in high-risk T2D.
Research strength: Strong

Potential Medical Uses

  • Type 2 diabetes
  • Chronic weight management (Saxenda)

Potential Benefits

  • A1C reduction
  • Weight loss
  • CV risk reduction

Known Side Effects

  • Nausea
  • Vomiting
  • Pancreatitis (rare)

Contraindications

  • MTC/MEN 2 history

Drug Interactions

  • Insulin, sulfonylureas

Administration Methods

  • Subcutaneous injection daily

Half-life

~13 hours

Reconstitution

Prefilled pen.

Storage & Handling

Refrigerate; in-use up to 30 days at room temp per label.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.